438 related articles for article (PubMed ID: 16891293)
21. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Pocock S; Wang D; Wilhelmsen L; Hennekens CH
Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin inhibition in heart failure.
McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Gales BJ; Bailey EK; Reed AN; Gales MA
Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Kubota T; Takeshita A
Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
[TBL] [Abstract][Full Text] [Related]
25. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
26. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
27. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
Bhakta S; Dunlap ME
Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
[TBL] [Abstract][Full Text] [Related]
29. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
30. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
31. Valsartan for the treatment of heart failure.
Latini R; Masson S; Staszewsky L; Maggioni AP
Expert Opin Pharmacother; 2004 Jan; 5(1):181-93. PubMed ID: 14680446
[TBL] [Abstract][Full Text] [Related]
32. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
33. [CHARM].
Momomura S
Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
[No Abstract] [Full Text] [Related]
34. Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.
Cohn JN
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):137-9. PubMed ID: 14608516
[TBL] [Abstract][Full Text] [Related]
35. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
[TBL] [Abstract][Full Text] [Related]
36. Candesartan for the management of heart failure: more than an alternative.
McKelvie RS
Expert Opin Pharmacother; 2006 Oct; 7(14):1945-56. PubMed ID: 17020420
[TBL] [Abstract][Full Text] [Related]
37. [Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Kuwabara Y; Komuro I
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):255-61. PubMed ID: 15768589
[No Abstract] [Full Text] [Related]
38. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Dulin BR; Krum H
Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
[TBL] [Abstract][Full Text] [Related]
39. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
40. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
